Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07784127 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07784127 · ClinicalTrials.gov record · last posted 2026-08-25

Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation

Name: Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation — clinical trial record (NCT07784127)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhaseNot applicable

SponsorThe Cleveland Clinic

Started2026-12

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

Participants will undergo evaluation with the Atmo capsule at two time points: at baseline before starting the GLP-1RA or dual agonist therapy and after the subject has been taking their GLP-1RA or dual agonist therapy for 3 months. The total expected time for patient participation is up to 4 months from the time they start their GLP-1RA or dual agonist therapy.

Trial Details

NCT Number	NCT07784127
Lead Sponsor	The Cleveland Clinic Collaborators: Atmo Biosciences Pty Ltd
Conditions	Diabetes
Enrollment	20 participants
Start Date	2026-12
Primary Completion	2028-08 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-25